Collaborative DevelopmentThe company announced a collaborative agreement with Thermo Fisher Scientific to jointly develop and potentially commercialize Mainz’s next generation mRNA-based screening tests for global markets.
Market AdoptionDecentralized commercial strategy includes partnering with lab groups to reduce marketing and infrastructure expenses, and gain access to large physician networks.
Product InnovationMainz Biomed's Next Generation Test leverages mRNA biomarkers to expand the ability to detect pre-cancerous advanced adenomas, enabling prevention of CRC.